BR112018005795A2 - inibidor de quinase de egfr e método de preparação e seu uso - Google Patents

inibidor de quinase de egfr e método de preparação e seu uso

Info

Publication number
BR112018005795A2
BR112018005795A2 BR112018005795A BR112018005795A BR112018005795A2 BR 112018005795 A2 BR112018005795 A2 BR 112018005795A2 BR 112018005795 A BR112018005795 A BR 112018005795A BR 112018005795 A BR112018005795 A BR 112018005795A BR 112018005795 A2 BR112018005795 A2 BR 112018005795A2
Authority
BR
Brazil
Prior art keywords
preparation
kinase inhibitor
egfr kinase
egfr
compound
Prior art date
Application number
BR112018005795A
Other languages
English (en)
Inventor
Zhang Chen
Ma Dawei
Cai Dongpo
Xia Hongguang
Yuan Junying
Wang Kailiang
Yu Qiang
Xia Shanghua
Original Assignee
Zhejiang Bossan Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Bossan Pharmaceutical Co Ltd filed Critical Zhejiang Bossan Pharmaceutical Co Ltd
Publication of BR112018005795A2 publication Critical patent/BR112018005795A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção proporciona o inibidor da quinase de egfr e um método de preparação e seu uso. especificamente, a presente invenção proporciona um composto como mostrado na fórmula (i), a definição de cada grupo neste sendo como descrito no relatório descritivo. o referido composto é um inibidor eficiente de egfr.
BR112018005795A 2015-09-25 2016-07-11 inibidor de quinase de egfr e método de preparação e seu uso BR112018005795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510622837.4A CN106554347B (zh) 2015-09-25 2015-09-25 Egfr激酶抑制剂及其制备方法和应用
PCT/CN2016/089679 WO2017049992A1 (zh) 2015-09-25 2016-07-11 Egfr激酶抑制剂及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112018005795A2 true BR112018005795A2 (pt) 2019-01-15

Family

ID=58385839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005795A BR112018005795A2 (pt) 2015-09-25 2016-07-11 inibidor de quinase de egfr e método de preparação e seu uso

Country Status (12)

Country Link
US (1) US10710979B2 (pt)
EP (1) EP3354647B1 (pt)
JP (1) JP6752283B2 (pt)
KR (1) KR20180096575A (pt)
CN (1) CN106554347B (pt)
AU (1) AU2016327857B2 (pt)
BR (1) BR112018005795A2 (pt)
CA (1) CA2999785C (pt)
RU (1) RU2018115278A (pt)
SG (1) SG11201802470SA (pt)
WO (1) WO2017049992A1 (pt)
ZA (1) ZA201802141B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020124191A (ru) 2015-10-01 2020-08-27 Потенза Терапевтикс, Инк. Анти-tigit антиген-связывающие белки и способы их применения
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) * 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
WO2012064706A1 (en) * 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
CN104583195B (zh) * 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
NO2718543T3 (pt) * 2014-02-04 2018-01-06
CN104860890B (zh) * 2015-04-29 2018-03-13 上海泓博智源医药股份有限公司 T790m突变型egfr的抑制剂及其在制备抗肿瘤药物中的应用
CN105461640B (zh) 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法

Also Published As

Publication number Publication date
CA2999785C (en) 2020-10-27
AU2016327857B2 (en) 2019-10-03
EP3354647B1 (en) 2022-08-24
CA2999785A1 (en) 2017-03-30
JP6752283B2 (ja) 2020-09-09
US10710979B2 (en) 2020-07-14
RU2018115278A3 (pt) 2019-10-28
SG11201802470SA (en) 2018-04-27
WO2017049992A1 (zh) 2017-03-30
CN106554347B (zh) 2020-10-30
US20180346444A1 (en) 2018-12-06
KR20180096575A (ko) 2018-08-29
ZA201802141B (en) 2019-01-30
RU2018115278A (ru) 2019-10-28
JP2018536698A (ja) 2018-12-13
EP3354647A4 (en) 2019-04-03
CN106554347A (zh) 2017-04-05
AU2016327857A1 (en) 2018-04-26
EP3354647A1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
CO2018005368A2 (es) Inhibidores pirazol de acc y usos de los mismos
BR112018005795A2 (pt) inibidor de quinase de egfr e método de preparação e seu uso
BR112015032539A2 (pt) compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase
DOP2016000173A (es) Heteroarilos y usos de estos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CR20150524A (es) Compuestos de heteroarilo y sus usos
ECSP16088985A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
CR20150462A (es) Inhibidores de erk y sus usos
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112015028171A8 (pt) Inibidores de acc e seu uso
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
BR112016009757A8 (pt) “inibidores do vírus sincicial respiratório com base em quinazolina”
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]